Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, stated, Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH. He noted that this approval complements the proven weight loss, cardiovascular benefits, and broader evidence linked to semaglutide
Currently undergoing shop testing in the US, the drink contains 15g of protein, 10g of fibre, essential vitamins and no added sugar, aiming to keep consumers feeling fuller for longer
Some overlap of the two medications in your system is expected and generally well tolerated
Higher concentrations increase cost and formulation instability, so many brands dilute to levels that are safe but marginally effective
10.1371/journal.pone.0026915 6
doi: 10.1172/jci.insight.140532